Market reports & researches
LOG IN | Services | Contact | Custom Research



Main Healthcare, Pharmaceuticals & Biotechnology Healthcare and drugs 25+ Business Development and Innovation Opportunities in Diabetes and Related Conditions - Emerging Opportunities to 2010
Publications

(Currently 512486 Items)


Partners


Healthcare and drugs / REPORT INFORMATION

25+ Business Development and Innovation Opportunities in Diabetes and Related Conditions - Emerging Opportunities to 2010

DateJan, 2001
Pages171
Price / format€7972 / Hard Copy

€7 972 

Report Information | Custom-Tailored Research | Product Trade Lead


Abstract:
 This comprehensive report provides a new, think-tank approach to the identification of business opportunities in diabetes. a special worldwide study which identifies and evaluates 25+ emerging business opportunities.

This thoroughly researched study provides in-depth analysis based on over 100 thought-leader interviews covering the innovation platforms which offer both differentiation and sustainable competitive advantages worth considering.





This report is designed to provide a useful tool to professionals in research and development (R&D), marketing, business development, licensing, and strategic planning who are, or are anticipating, involvement in the discovery, development, licensing, and/or marketing of therapeutics for the treatment of Type I diabetes, Type II diabetes, nephropathy, neuropathy, and retinopathy.





Table of contents:
 EXECUTIVE SUMMARY.........................................................................................................................................I
SECTION 1 INTRODUCTION................................................................................................................................ 1
INVESTIGATION........................................................... 1
1.2 METHODOLOGY OF INVESTIGATION................................................................................................ 2
1.3 LIMITATIONS OF INVESTIGATION ..................................................................................................... 3
SECTION 2 DELPHI PANEL AND THOUGHT LEADER INTERVIEW: DISCUSSION AND SUMMARY
OF DIABETES INNOVATION.................................................................................................... 5
2.1 INTRODUCTION ..................................................................................................................................... 5
2.2 RESULTS OF DELPHI PANEL INTERVIEWS....................................................................................... 6
2.3 DELPHI SUMMARY.............................................................................................................................. 18
SECTION 3 TYPE I DIABETES BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES . 21
3.1 INTRODUCTION TO THE DISEASE STATE AND ITS EPIDEMIOLOGY ....................................... 21
3.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY......................................................... 24
3.3 PRODUCT TECHNOLOGY ANALYSIS ............................................................................................... 26
3.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 33
3.5 BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITY IDENTIFICATION ................ 35
SECTION 4 TYPE II DIABETES BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES 39
4.1 INTRODUCTION TO THE DISEASE STATE AND ITS EPIDEMIOLOGY ....................................... 39
4.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY......................................................... 44
4.3 PRODUCT TECHNOLOGY ANALYSIS ............................................................................................... 48
4.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 60
4.5 BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITY IDENTIFICATION ................ 64
SECTION 5 DIABETIC NEPHROPATHY BUSINESS DEVELOPMENT AND INNOVATION
OPPORTUNITIES...................................................................................................................... 71
5.1 INTRODUCTION TO THE DISEASE STATE AND ITS EPIDEMIOLOGY ....................................... 71
5.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY......................................................... 75
5.3 PRODUCT TECHNOLOGY ANALYSIS ............................................................................................... 76
5.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 82
5.5 BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITY IDENTIFICATION ................ 83
SECTION 6 DIABETIC NEUROPATHY BUSINESS DEVELOPMENT AND INNOVATION
OPPORTUNITIES...................................................................................................................... 87
6.1 INTRODUCTION TO THE DISEASE STATE AND ITS EPIDEMIOLOGY ....................................... 87
6.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY......................................................... 91
6.3 PRODUCT TECHNOLOGY ANALYSIS ............................................................................................... 91
6.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 96
6.5 BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITY IDENTIFICATION ................ 97
ii
SECTION 7 DIABETIC RETINOPATHY BUSINESS DEVELOPMENT AND INNOVATION
OPPORTUNITIES.................................................................................................................... 101
7.1 INTRODUCTION TO THE DISEASE STATE AND ITS EPIDEMIOLOGY ..................................... 101
7.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY....................................................... 105
7.3 PRODUCT TECHNOLOGY ANALYSIS ............................................................................................. 105
7.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 111
7.5 BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITY IDENTIFICATION .............. 112
SECTION 8 TECHNOLOGY PLATFORMS PRODUCT TECHNOLOGIES IMPACTING DIABETES
THERAPEUTICS ...................................................................................................................... 115
8.1 INTRODUCTION TO PRODUCT TECHNOLOGIES IMPACTING DIABETES THERAPEUTICS 115
8.2 ANGIOGENISIS INHIBITORS............................................................................................................. 116
8.3 ANTIHYPERTENSIVE AGENTS......................................................................................................... 117
8.4 CELL THERAPY .................................................................................................................................. 118
8.5 ENZYME INHIBITORS ........................................................................................................................ 120
8.6 GROWTH FACTORS ............................................................................................................................ 122
8.7 GLYCATION ALTERING AGENTS.................................................................................................... 124
8.8 ALDOSE REDUCTASE INHIBITORS (ARI)....................................................................................... 125
8.9 ADVANCED GLYCATION END PRODUCT (AGE) INHIBITORS .................................................. 125
8.10 HORMONES ......................................................................................................................................... 126
8.11 IMMUNOTHERAPY ............................................................................................................................. 127
8.12 ADHESION MOLECULES ................................................................................................................... 128
8.13 VACCINES............................................................................................................................................ 129
8.14 INSULIN AND INSULIN ANALOGS .................................................................................................. 129
8.15 INSULIN ANALOGUES AND AGONISTS ......................................................................................... 130
8.16 INSULIN DELIVERY SYSTEMS......................................................................................................... 130
8.17 SULFONYLUREAS.............................................................................................................................. 133
8.18 INSULINOTROPIC AGENTS............................................................................................................... 133
8.19 GLP-1..................................................................................................................................................... 134
8.20 INSULIN SENSITIZERS ....................................................................................................................... 135
8.21 MOLECULAR....................................................................................................................................... 137
8.22 NEUROTRANSMITTER MODULATORS ..........................................................................................140
8.23 SIGNAL TRANSDUCTION MODULATORS......................................................................................141
8.24 THIAZOLIDINES, PPAR AGONISTS AND RXR AGONISTS .......................................................... 143
8.25 OTHER TECHNOLOGIES................................................................................................................... 145
SECTION 9 COMPANY PROFILES OF INNOVATIVE FIRMS REPRESENTING ACQUISITIONS,
LICENSING, AND COMARKETING OPPORTUNITIES IN DIABETES THERAPY.... 147
9.1 ALLERGAN.......................................................................................................................................... 147
9.2 ALIZYME.............................................................................................................................................. 147
9.3 ALTEON................................................................................................................................................ 148
9.4 AMYLIN................................................................................................................................................ 148
9.5 ASTA MEDICA .................................................................................................................................... 149
9.6 BECTON DICKINSON......................................................................................................................... 149
9.7 BIOMEDICA FOSCAMA...................................................................................................................... 150
9.8 BIOSTRATUM...................................................................................................................................... 150
9.9 BIOTECH HOLDINGS......................................................................................................................... 150
9.10 CALYX THERAPEUTICS .................................................................................................................... 151
9.11 COELACANTH..................................................................................................................................... 151
9.12 COLLAGENEX PHARMACEUTICALS.............................................................................................. 152
9.13 DAINIPPON.......................................................................................................................................... 152
9.14 DESMOS ............................................................................................................................................... 152
9.15 DEVELOGEN ....................................................................................................................................... 153
9.16 DR REDDY’S RESEARCH FOUNDATION........................................................................................ 153
9.17 EXOCELL ............................................................................................................................................. 153
iii
9.18 FUJISAWA............................................................................................................................................ 154
9.19 GILEAD SCIENCES............................................................................................................................. 154
9.20 INSMED ................................................................................................................................................ 155
9.21 ISIS ..................................................................................................................................................... 156
9.22 JAPAN TOBACCO ............................................................................................................................... 156
9.23 KERYX BIOPHARMACEUTICALS .................................................................................................... 157
9.24 KYOWA HAKKO................................................................................................................................. 157
9.25 MAXIA PHARMACEUTICALS ........................................................................................................... 158
9.26 MEDIGENE........................................................................................................................................... 158
9.27 MERCK KGAA..................................................................................................................................... 159
9.28 METABOLEX....................................................................................................................................... 159
9.29 NEUROCHEM ...................................................................................................................................... 160
9.30 NEUROGEN.......................................................................................................................................... 160
9.31 NEXELL (FORMERLY VIMRX PHARMACEUTICALS).................................................................. 160
9.32 NIH ..................................................................................................................................................... 161
9.33 NIPPON CHEMIPHAR......................................................................................................................... 161
9.34 NISSAN CHEMICAL ............................................................................................................................ 162
9.35 PEPTECH .............................................................................................................................................. 162
9.36 PHARMACEUTICAL DISCOVERY .................................................................................................... 162
9.37 PHOTOVISION..................................................................................................................................... 163
9.38 PHYLOMED ......................................................................................................................................... 163
9.39 PROBIODRUG...................................................................................................................................... 163
9.40 PROTEIN DELIVERY (NOW NOBEX CORPORATION).................................................................. 164
9.41 PROVALIS ............................................................................................................................................ 164
9.42 QUADRANT HEALTHCARE............................................................................................................... 165
9.43 SANWA KAGAKU KENKYUSHO...................................................................................................... 166
9.44 SERTOLI TECHNOLOGIES................................................................................................................. 166
9.45 SERVIER............................................................................................................................................... 167
9.46 STEMCELLS......................................................................................................................................... 167
9.47 SUNTORY............................................................................................................................................. 168
9.48 SUPERGEN........................................................................................................................................... 168
9.49 TAKEDA............................................................................................................................................... 168
9.50 TANABE SEIYAKU............................................................................................................................. 169
9.51 TELIK (FORMERLY TERRAPIN TECHNOLOGIES) ........................................................................ 169
9.52 VICAL ................................................................................................................................................... 169
9.53 VIVORX................................................................................................................................................ 170
9.54 YISSUM ................................................................................................................................................ 170
9.55 WATSON LABS (FORMERLY THERATECH)................................................................................... 170
9.56 ZYCOS .................................................................................................................................................. 170
iv
DETAILED TABLE OF CONTENTS
EXECUTIVE SUMMARY...............................................................................................................................................i
Current Therapeutic Regimens.......................................................................................................................................vii
Future Treatments...........................................................................................................................................................vii
SECTION 1 INTRODUCTION................................................................................................................................ 1
1.1 SCOPE AND OBJECTIVES OF RESEARCH INVESTIGATION........................................................... 1
1.2 METHODOLOGY OF INVESTIGATION................................................................................................ 2
1.3 LIMITATIONS OF INVESTIGATION ..................................................................................................... 3
SECTION 2 DELPHI PANEL AND THOUGHT LEADER INTERVIEW: DISCUSSION AND SUMMARY
OF DIABETES INNOVATION.................................................................................................... 5
2.1 INTRODUCTION ..................................................................................................................................... 5
2.2 RESULTS OF DELPHI PANEL INTERVIEWS....................................................................................... 6
2.2.1 Diabetic complications.................................................................................................................... 6
2.2.2 A.G.E.s and Diabetic Complications................................................................................................ 7
2.2.3 Impact of ACE Inhibitors on Diabetes ............................................................................................. 8
2.2.4 Combination Therapy in Type II Diabetes ....................................................................................... 9
2.2.5 New Approaches for Insulin Therapy............................................................................................. 11
2.2.6 Islet Cell Transplantation............................................................................................................... 12
2.2.7 Thiazolidines and PPARs ............................................................................................................... 13
2.2.8 GLP-1............................................................................................................................................ 15
2.2.9 Genomics....................................................................................................................................... 16
2.2.10 Future Trends and Issues in Diabetes ............................................................................................ 16
2.3 DELPHI SUMMARY.............................................................................................................................. 18
Current Therapeutic Regimens.......................................................................................................................................18
Future Treatments...........................................................................................................................................................19
SECTION 3 TYPE I DIABETES BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES . 21
3.1 INTRODUCTION TO THE DISEASE STATE AND ITS EPIDEMIOLOGY ....................................... 21
3.1.1 Epidemiology................................................................................................................................. 21
3.1.2 Etiology ......................................................................................................................................... 22
3.1.3 Pathophysiology ............................................................................................................................. 22
3.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY......................................................... 24
3.3 PRODUCT TECHNOLOGY ANALYSIS ............................................................................................... 26
3.3.1 Current Therapeutics ..................................................................................................................... 31
3.3.2 Near-term Therapeutics.................................................................................................................. 31
3.3.3 Longer-term Therapeutics .............................................................................................................. 32
3.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 33
3.5 BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITY IDENTIFICATION ................ 35
SECTION 4 TYPE II DIABETES BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITIES 39
4.1 INTRODUCTION TO THE DISEASE STATE AND ITS EPIDEMIOLOGY ....................................... 39
4.1.1 Epidemiology................................................................................................................................. 39
4.1.2 Risk Factors for NIDDM................................................................................................................ 39
4.1.3 Prevalence..................................................................................................................................... 40
v
4.1.4 Etiology ......................................................................................................................................... 40
4.1.5 Diagnosis of Type II Diabetes ........................................................................................................ 41
4.1.6 Mortality........................................................................................................................................ 41
4.1.7 Current Therapy: Value And Limitations ....................................................................................... 41
4.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY......................................................... 44
4.2.1 Recent events in diabetes Type II ................................................................................................... 44
4.3 PRODUCT TECHNOLOGY ANALYSIS ............................................................................................... 48
4.3.1 Assumption Structure ..................................................................................................................... 52
4.3.2 Current Therapeutics ..................................................................................................................... 53
4.3.3 Near-term Therapeutics.................................................................................................................. 55
4.3.4 Longer-term Therapeutics .............................................................................................................. 56
4.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 60
4.5 BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITY IDENTIFICATION ................ 64
SECTION 5 DIABETIC NEPHROPATHY BUSINESS DEVELOPMENT AND INNOVATION
OPPORTUNITIES...................................................................................................................... 71
5.1 INTRODUCTION TO THE DISEASE STATE AND ITS EPIDEMIOLOGY ....................................... 71
5.1.1 Epidemiology................................................................................................................................. 71
5.1.2 Definition....................................................................................................................................... 72
5.1.3 Etiology ......................................................................................................................................... 73
5.1.4 Pathophysiology ............................................................................................................................. 73
5.1.5 Diagnosis....................................................................................................................................... 75
5.1.6 Treatment ...................................................................................................................................... 75
5.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY......................................................... 75
5.3 PRODUCT TECHNOLOGY ANALYSIS ............................................................................................... 76
5.3.1 Assumption Structure ..................................................................................................................... 79
5.3.2 Current Therapeutics ..................................................................................................................... 79
5.3.3 Near-term Therapeutics.................................................................................................................. 80
5.3.4 Longer-term Therapeutics .............................................................................................................. 81
5.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 82
5.5 BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITY IDENTIFICATION ................ 83
SECTION 6 DIABETIC NEUROPATHY BUSINESS DEVELOPMENT AND INNOVATION
OPPORTUNITIES...................................................................................................................... 87
6.1 INTRODUCTION TO THE DISEASE STATE AND ITS EPIDEMIOLOGY ....................................... 87
6.1.1 Epidemiology................................................................................................................................. 87
6.1.2 Definition....................................................................................................................................... 87
6.1.3 Types of Neuropathy...................................................................................................................... 88
6.1.4 Etiology ......................................................................................................................................... 88
6.1.5 Pathophysiology ............................................................................................................................. 89
6.1.6 Diagnosis....................................................................................................................................... 90
6.1.7 Treatment ...................................................................................................................................... 90
6.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY......................................................... 91
6.3 PRODUCT TECHNOLOGY ANALYSIS ............................................................................................... 91
6.3.1 Assumption Structure ..................................................................................................................... 94
6.3.2 Current Therapeutics ..................................................................................................................... 94
6.3.3 Near-term Therapeutics.................................................................................................................. 94
6.3.4 Longer-term Therapeutics .............................................................................................................. 94
6.4 MARKET ANALYSIS AND FORECAST .............................................................................................. 96
6.5 BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITY IDENTIFICATION ................ 97
SECTION 7 DIABETIC RETINOPATHY BUSINESS DEVELOPMENT AND INNOVATION
OPPORTUNITIES.................................................................................................................... 101
7.1 INTRODUCTION TO THE DISEASE STATE AND ITS EPIDEMIOLOGY ..................................... 101
7.1.1 Epidemiology............................................................................................................................... 101
7.1.2 Definition..................................................................................................................................... 101
7.1.3 Epidemiology............................................................................................................................... 102
7.1.4 Etiology and Pathophysiology...................................................................................................... 103
7.1.5 Diagnosis..................................................................................................................................... 104
7.2 EVALUATION OF INNOVATION ACTIVITIES UNDER WAY....................................................... 105
7.3 PRODUCT TECHNOLOGY ANALYSIS ............................................................................................. 105
7.3.1 Assumption Structure ................................................................................................................... 108
7.3.2 Current Therapeutics ................................................................................................................... 108
7.3.3 Near-term Therapeutics................................................................................................................ 109
7.3.4 Longer-term Therapeutics ............................................................................................................ 110
7.4 MARKET ANALYSIS AND FORECAST ............................................................................................ 111
7.5 BUSINESS DEVELOPMENT AND INNOVATION OPPORTUNITY IDENTIFICATION .............. 112
SECTION 8 TECHNOLOGY PLATFORMS PRODUCT TECHNOLOGIES IMPACTING DIABETES
THERAPEUTICS ...................................................................................................................... 115
8.1 INTRODUCTION TO PRODUCT TECHNOLOGIES IMPACTING DIABETES THERAPEUTICS 115
8.2 ANGIOGENISIS INHIBITORS............................................................................................................. 116
8.3 ANTIHYPERTENSIVE AGENTS......................................................................................................... 117
8.3.1 ACE inhibitors............................................................................................................................. 117
8.3.2 Angiotensin II Antagonists ........................................................................................................... 118
8.4 CELL THERAPY .................................................................................................................................. 118
8.5 ENZYME INHIBITORS ........................................................................................................................ 120
8.5.1 Pancreatic Lipase......................................................................................................................... 120
8.5.2 Hormone-Sensitive Lipase............................................................................................................ 120
8.5.3 Alpha Glucosidase Inhibitors ....................................................................................................... 121
8.5.4 Glycogen Phosphorylase.............................................................................................................. 121
8.5.5 CPT-1 (carnitine palmytoyl transferase I) ................................................................................... 121
8.6 GROWTH FACTORS ............................................................................................................................ 122
8.6.1 Insulin-like Growth Factor (IGF-1) ............................................................................................. 122
8.6.2 Neurotrophic Growth Factors...................................................................................................... 123
8.7 GLYCATION ALTERING AGENTS.................................................................................................... 124
8.8 ALDOSE REDUCTASE INHIBITORS (ARI)....................................................................................... 125
8.9 ADVANCED GLYCATION END PRODUCT (AGE) INHIBITORS .................................................. 125
8.10 HORMONES ......................................................................................................................................... 126
8.10.1 Leptin........................................................................................................................................... 126
8.10.2 Amylin.......................................................................................................................................... 126
8.10.3 Steroid Hormones........................................................................................................................ 126
8.10.4 Glucagon ..................................................................................................................................... 126
8.10.5 Glucagon Antagonists .................................................................................................................. 127
8.11 IMMUNOTHERAPY ............................................................................................................................. 127
8.11.1 Immunomodulators...................................................................................................................... 127
8.12 ADHESION MOLECULES ................................................................................................................... 128
8.13 VACCINES............................................................................................................................................ 129
8.14 INSULIN AND INSULIN ANALOGS .................................................................................................. 129
8.15 INSULIN ANALOGUES AND AGONISTS ......................................................................................... 130
8.16 INSULIN DELIVERY SYSTEMS......................................................................................................... 130
8.16.1 Inhaled Insulin............................................................................................................................. 131
8.16.2 Oral Insulin ................................................................................................................................. 132
8.16.3 insulin secretagogues ................................................................................................................... 132
8.17 SULFONYLUREAS.............................................................................................................................. 133
8.18 INSULINOTROPIC AGENTS............................................................................................................... 133
8.19 GLP-1..................................................................................................................................................... 134
8.20 INSULIN SENSITIZERS ....................................................................................................................... 135
8.20.1 Biguanides................................................................................................................................... 135
8.20.2 Glucose Uptake Mediators ........................................................................................................... 136
8.20.3 Oxadiazole................................................................................................................................... 136
8.21 MOLECULAR....................................................................................................................................... 137
vii
8.21.1 Gene therapy ............................................................................................................................... 137
8.21.2 Antisense Technology ................................................................................................................... 138
8.21.3 Genomics..................................................................................................................................... 139
8.22 NEUROTRANSMITTER MODULATORS ..........................................................................................140
8.22.1 Adrenergic Agents ........................................................................................................................ 140
8.22.2 Dopamine .................................................................................................................................... 140
8.23 SIGNAL TRANSDUCTION MODULATORS......................................................................................141
8.23.1 Protein Kinase C (PKC) Inhibitors .............................................................................................. 141
8.23.2 Phosphodiesterase (PDE) Inhibitors............................................................................................ 142
8.23.3 Insulin Signaling, Tyrosine kinase/phosphatase........................................................................... 142
8.24 THIAZOLIDINES, PPAR AGONISTS AND RXR AGONISTS .......................................................... 143
8.24.1 Thiazolidines ............................................................................................................................... 144
8.24.2 PPAR Agonists ............................................................................................................................. 144
8.24.3 RXR Agonists............................................................................................................................... 144
8.25 OTHER TECHNOLOGIES................................................................................................................... 145
SECTION 9 COMPANY PROFILES OF INNOVATIVE FIRMS REPRESENTING ACQUISITIONS,
LICENSING, AND COMARKETING OPPORTUNITIES IN DIABETES THERAPY.... 147
9.1 ALLERGAN.......................................................................................................................................... 147
9.2 ALIZYME.............................................................................................................................................. 147
9.3 ALTEON................................................................................................................................................ 148
9.4 AMYLIN................................................................................................................................................ 148
9.5 ASTA MEDICA .................................................................................................................................... 149
9.6 BECTON DICKINSON......................................................................................................................... 149
9.7 BIOMEDICA FOSCAMA...................................................................................................................... 150
9.8 BIOSTRATUM...................................................................................................................................... 150
9.9 BIOTECH HOLDINGS......................................................................................................................... 150
9.10 CALYX THERAPEUTICS .................................................................................................................... 151
9.11 COELACANTH..................................................................................................................................... 151
9.12 COLLAGENEX PHARMACEUTICALS.............................................................................................. 152
9.13 DAINIPPON.......................................................................................................................................... 152
9.14 DESMOS ............................................................................................................................................... 152
9.15 DEVELOGEN ....................................................................................................................................... 153
9.16 DR REDDY’S RESEARCH FOUNDATION........................................................................................ 153
9.17 EXOCELL ............................................................................................................................................. 153
9.18 FUJISAWA............................................................................................................................................ 154
9.19 GILEAD SCIENCES............................................................................................................................. 154
9.20 INSMED ................................................................................................................................................ 155
9.21 ISIS ..................................................................................................................................................... 156
9.22 JAPAN TOBACCO ............................................................................................................................... 156
9.23 KERYX BIOPHARMACEUTICALS .................................................................................................... 157
9.24 KYOWA HAKKO................................................................................................................................. 157
9.25 MAXIA PHARMACEUTICALS ........................................................................................................... 158
9.26 MEDIGENE........................................................................................................................................... 158
9.27 MERCK KGAA..................................................................................................................................... 159
9.28 METABOLEX....................................................................................................................................... 159
9.29 NEUROCHEM ...................................................................................................................................... 160
9.30 NEUROGEN.......................................................................................................................................... 160
9.31 NEXELL (FORMERLY VIMRX PHARMACEUTICALS).................................................................. 160
9.32 NIH ..................................................................................................................................................... 161
9.33 NIPPON CHEMIPHAR......................................................................................................................... 161
9.34 NISSAN CHEMICAL ............................................................................................................................ 162
9.35 PEPTECH .............................................................................................................................................. 162
9.36 PHARMACEUTICAL DISCOVERY .................................................................................................... 162
9.37 PHOTOVISION..................................................................................................................................... 163
9.38 PHYLOMED ......................................................................................................................................... 163
viii
9.39 PROBIODRUG...................................................................................................................................... 163
9.40 PROTEIN DELIVERY (NOW NOBEX CORPORATION).................................................................. 164
9.41 PROVALIS ............................................................................................................................................ 164
9.42 QUADRANT HEALTHCARE............................................................................................................... 165
9.43 SANWA KAGAKU KENKYUSHO...................................................................................................... 166
9.44 SERTOLI TECHNOLOGIES................................................................................................................. 166
9.45 SERVIER............................................................................................................................................... 167
9.46 STEMCELLS......................................................................................................................................... 167
9.47 SUNTORY............................................................................................................................................. 168
9.48 SUPERGEN........................................................................................................................................... 168
9.49 TAKEDA............................................................................................................................................... 168
9.50 TANABE SEIYAKU............................................................................................................................. 169
9.51 TELIK (FORMERLY TERRAPIN TECHNOLOGIES) ........................................................................ 169
9.52 VICAL ................................................................................................................................................... 169
9.53 VIVORX................................................................................................................................................ 170
9.54 YISSUM ................................................................................................................................................ 170
9.55 WATSON LABS (FORMERLY THERATECH)................................................................................... 170
9.56 ZYCOS .................................................................................................................................................. 170
ix
LIST OF FIGURES
Figure ES-1 Product Development Activity in Diabetes by Disease State ................................ iv
Figure ES-2 Product Development Activity in Diabetes Therapy by Phase of Development .... v
Figure ES-3 Unpartnered vs. Partnered Programs by Phase of Development ........................... vi
Figure 3.1 Market Impact Matrix for Technology Platforms in Type I Diabetes Therapy.... 28
Figure 3.2 WW Forecast for Type I Diabetes Therapy by Technology Platform .................. 29
Figure 3.3 US Forecast for Insulin Delivery Platforms.......................................................... 30
Figure 4.1 Market Impact Matrix for Technology Platforms in Type II Diabetes Therapy... 51
Figure 4.2 WW Forecast for Type II Diabetes Therapy by Technology Platform................. 52
Figure 5.1 Market Impact Matrix for Technology Platforms in Diabetic Nephropathy
Therapy.................................................................................................................. 78
Figure 5.2 WW Forecast for Diabetic Nephropathy Therapy by Technology Platform ........ 79
Figure 6.1 Market Impact Matrix for Technology Platforms in Diabetic Neuropathy
Therapy.................................................................................................................. 93
Figure 6.2 WW Forecast for Diabetic Neuropathy Therapy by Technology Platform .......... 93
Figure 7.1 Market Impact Matrix for Technology Platforms in Diabetic Retinopathy
Therapy................................................................................................................ 107
Figure 7.2 WW Forecast for Diabetic Retinopathy Therapy by Technology Platform........ 108
x
LIST OF TABLES
Table ES-1 US Sales Forecast for Major Diabetes Categories ...............................................viii
Table ES-2 Opportunity Sorting Matrix for All Diabetes Therapies ........................................ xi
Table 3.1 Product Development Activity for Type I Diabetes Therapy by Phase of
Development ......................................................................................................... 27
Table 3.2 US Market Forecast for Type I Diabetes Therapy by Technology....................... 34
Table 3.3 Opportunity Sorting Matrix for Type I Diabetes Therapy .................................... 36
Table 3.4 Product Development Activity for Type I Diabetes Therapy ............................... 37
Table 4.1 Product Development Activity for Type II Diabetes Therapy by Phase of
Development ......................................................................................................... 49
Table 4.2 US Market Forecast for Type II Diabetes Therapy by Technology...................... 63
Table 4.3 Opportunity Sorting Matrix for Type II Diabetes Therapy................................... 65
Table 4.4 Product Development Activity for Type II Diabetes Therapy.............................. 67
Table 5.1 Product Development Activity for Diabetic Nephropathy Therapy by Phase of
Development ......................................................................................................... 76
Table 5.2 US Market Forecast for Diabetic Nephropathy Therapy by Technology ............. 83
Table 5.3 Opportunity Sorting Matrix for Diabetic Nephropathy Therapy .......................... 84
Table 5.4 Product Development Activity for Diabetic Nephropathy Therapy ..................... 86
Table 6.1 Product Development Activity for Diabetic Neuropathy Therapy by Phase of
Development ......................................................................................................... 92
Table 6.2 US Market Forecast for Diabetic Neuropathy Therapy by Technology ............... 97
Table 6.3 Opportunity Sorting Matrix for Diabetic Neuropathy Therapy ............................ 98
Table 6.4 Product Development Activity for Diabetic Neuropathy Therapy ....................... 99
Table 7.1 Product Development Activity for Diabetic Retinopathy Therapy by Phase of
Development ....................................................................................................... 106
Table 7.2 US Market Forecast for Diabetic Retinopathy Therapy by Technology ............ 112
Table 7.3 Opportunity Sorting Matrix for Diabetic Retinopathy Therapy ......................... 113
Table 7.4 Product Development Activity for Diabetic Retinopathy Therapy..................... 114




Order this report

  Company name:
  Contact person:
  Phone/fax:
  Email:
  Comments:
   


Product Trade Lead
0 leads found


Add New Buy/Sell Lead

© 2007-2010 MarketReportFinder.com